Ligand price target raised to $95 from $90 at Roth MKM

Roth MKM analyst Scott Henry raised the firm’s price target on Ligand to $95 from $90 and keeps a Buy rating on the shares. The analyst cites the company’s "robust" Q4 results and sees the near-term lever to the model coming from Filspari revenue. Filspari launch and the upcoming pipeline events should serve as catalysts for a higher valuation, the firm tells investors in a research note.